News · 26 weeks37-100%
2026-03-012026-08-23
Mix2490d
- SEC Filings12(50%)
- Other10(42%)
- M&A1(4%)
- Analyst1(4%)
Latest news
25 items- SECAmendment: SEC Form 6-K/A filed by Inventiva S.A.6-K/A - Inventiva S.A. (0001756594) (Filer)
- PRCorrection: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026. On page 2, the potential proceeds for the Tranche C of the Debt Financing Transaction was mistakenly stated as €20 million. The correct figure is €55 million. All other information in the press release remains unchanged. As a result, the corrected version shall read as follows: Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical c
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva Announces Preliminary Financial Results for the First Half of 2026¹Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 29, 2026 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported certain preliminary financial results for the first half of 2026, including its cash, cash equivalents and revenues. Preliminary Financial Results As at June 30, 2026, the Company’s cash and cash equivalents amounted to €166.1 million and €67.8 million in shor
- ANALYSTCantor Fitzgerald initiated coverage on InventivaCantor Fitzgerald initiated coverage of Inventiva with a rating of Overweight
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB WarrantsDaix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), is pleased to announce the completion of the final step of the transactions previously announced on June 2, 2026 (the "Combined Transaction") through the issuance of approximately 15.7 million new warrants (bons de souscription d’actions) (the "New EIB Warrants") to the European Investment Bank (the "EIB") and the surrender and cancellation of all remaining warrants originally issued
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRResults of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026Daix (France), New York City (New York, United States), July 2, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the results of the votes of its Combined Shareholders’ Meeting. The Combined Shareholders' Meeting was held on Tuesday June 30, 2026, at 2 p.m. at Hôtel Villa M, 24-30 Bd Pasteur, 75015 Paris (France), under the chairmanship of Mr. Andrew Obenshain, Chief Executive Officer of Inventiva. Mr. Andrew Obenshain proceeded to the usual formalities of the opening of the meeting, in particu
- PRClaret Capital Partners participates in €130m financing for InventivaClaret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASHClaret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financingLatest in a series of late stage, European biotech investments by Claret Capital as part of its expansion in life sciences London, 16 June, 2026, Claret Capital Partners (‘Claret'), Europe's largest independent growth debt fund manager has made an investment through its funds, of €43m in Inventiva (Euronext Paris and NASDAQ:IVA), a clinical-stage biopharmaceutical company developing an oral therapy for the tr
- PRClaret Capital Partners participates in €130m financing for Inventiva to support Phase 3 developmentClaret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASHClaret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financingLatest in a series of late stage, European biotech investments by Claret Capital as part of its expansion in life sciences London, 16 June, 2026, Claret Capital Partners (‘Claret'), Europe's largest independent growth debt fund manager has made an investment through its funds, of €43m in Inventiva (Euronext Paris and NASDAQ:IVA), a clinical-stage biopharmaceutical company developing an oral therapy for the tr
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt FinancingRepaid in full the existing EIB Loans1 in an amount of approximately €62 million and completed repurchase of all 2,266,023 existing EIB Tranche A Warrants and 700,000 of existing EIB Tranche B Warrants2 (corresponding to approximately 22.7 million Underlying Shares) for a repurchase price of €50 million Issued the Tranche A Convertible Bonds (€35 million) and the Tranche B Amortized Bonds (€40 million), for an initial aggregate drawdown of €75 million under the Debt Financing Transaction3 with funds and accounts managed by BlackRock and Claret Capital Partners Daix (France), New York City (New York, United States), June 12, 2026 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or th
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRCombined General Meeting of June 30, 2026 - Availability of the Preparatory DocumentsDaix (France), New York City (New York, United States), June 9,2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the availability of the preparatory documents for the Combined General Meeting of June 30, 2026. Shareholders are invited to participate in the Combined General Meeting that will be held on June 30, 2026 at 2 p.m. at Hôtel Villa M, 24 – 30 Boulevard Pasteur, 75015 Paris (France). The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- SECSEC Form 424B5 filed by Inventiva S.A.424B5 - Inventiva S.A. (0001756594) (Filer)
- SECSEC Form FWP filed by Inventiva S.A.FWP - Inventiva S.A. (0001756594) (Subject)
- PRInventiva Announces Trading Resumption of its Ordinary Shares on Euronext ParisDaix (France), New York City (New York, United States), June 2, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 3:30 p.m. CEST. Trading of the ordinary shares of the Company was halted, at the Company's request, on June 2, 2026 from 9:00 a.m. CEST, in the context of the previously announced Debt Financing Transaction and Offering of American Depositary Shares in the United States (each representing
- PRInventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 ReadoutSecured a new debt financing with funds and accounts managed by BlackRock and Claret Capital Partners, respectively for up to €130 million in committed tranches, subject to conditions, plus an additional uncommitted tranche of up to €20 million, to replace its existing EIB loan ahead of maturity and extend its debt maturity profile to 2030Simplifying its capital structure with agreement to repurchase existing warrants issued in favor of the EIB, thereby eliminating 60% of the dilution protected EIB warrants (exercisable into 22.7 million shares), at a 40% discount to intrinsic value, and restructuring the remaining EIB warrants on terms that do not contain dilution protectionPriced an underw
- SECSEC Form F-3ASR filed by Inventiva S.A.F-3ASR - Inventiva S.A. (0001756594) (Filer)
- PRInventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext ParisDaix (France), New York City (New York, United States), June 2, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announces that the listing of its ordinary shares on the regulated market of Euronext Paris will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST. This suspension comes ahead of a proposed financing transaction, details of which will be announced in a new communication of the Company. This suspension will be effective until a new communication is
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
IVA FAQ
7 questionsWhat does Inventiva S.A. do?
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie...Where does IVA stock trade?
Inventiva S.A. (IVA) is listed on NASDAQ.What sector and industry is IVA in?
Inventiva S.A. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Inventiva S.A. go public?
Inventiva S.A. (IVA) completed its IPO in 2020.What are analysts saying about IVA?
Inventiva S.A. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-07-17. Recent price targets range from $1200.00 to $2600.00.What companies are similar to IVA?
Notable peers in the same industry include GNFT (GENFIT S.A.), GLTO (Galecto Inc.), CMMB (Chemomab Therapeutics Ltd.). Compare IVA side-by-side with any of them on Quantisnow.How can I track IVA on Quantisnow?
Quantisnow aggregates Inventiva S.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IVA to receive live email and push alerts on every new disclosure.